Qualigen Therapeutics, Inc. (QLGN)

USD 3.9

(-4.88%)

Market Cap (In USD)

2.87 Million

Revenue (In USD)

5.2 Million

Net Income (In USD)

-13.41 Million

Avg. Volume

11.75 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.336-30.5
PE
-
EPS
-
Beta Value
0.135
ISIN
US74754R2022
CUSIP
74754R103
CIK
1460702
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Michael S. Poirier
Employee Count
-
Website
https://www.qualigeninc.com
Ipo Date
2015-06-23
Details
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.